Idexx Laboratories (IDXX) closed at $557.93 on October 20, 2026, up 0.4% from the previous close, on volume of 378,351 shares (30-day average 503,288).
Data as of October 20, 2026.
Quality stocks breaking out as mid-cycle shift accelerates - Morgan Stanley
Seeking Alpha News (Mon, 19-Oct 11:47 AM ET)
Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus
Seeking Alpha News (Sun, 18-Oct 9:05 AM ET)
OCUL, IDXX, BIIB, BFLY, TMUS Trending With Analysts
TipRanks (Sat, 17-Oct 5:01 AM ET)
Tech stocks drag Nasdaq 2% lower; sheds over 4% for the week
Seeking Alpha News (Fri, 16-Oct 4:35 PM ET)
These S&P 500 stocks lead in capital efficiency - BofA
Seeking Alpha News (Fri, 16-Oct 12:14 PM ET)
Midday Pulse: S&P 500 top intraday gainers
Seeking Alpha News (Fri, 16-Oct 12:03 PM ET)
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
Business Wire (Thu, 1-Oct 11:30 AM ET)
PRNewswire (Wed, 30-Sep 9:00 AM ET)
Business Wire (Thu, 17-Sep 3:00 AM ET)
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
Business Wire (Wed, 16-Sep 7:00 AM ET)
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Idexx Laboratories trades on the NASDAQ stock market under the symbol IDXX.
As of October 20, 2026, IDXX stock price climbed to $557.93 with 378,351 million shares trading.
IDXX has a beta of 0.47, meaning it tends to be less sensitive to market movements. IDXX has a correlation of 0.04 to the broad based SPY ETF.
IDXX has a market cap of $43.95 billion. This is considered a Large Cap stock.
Last quarter Idexx Laboratories reported $1 billion in Revenue and $4.27 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.33.
In the last 3 years, IDXX traded as high as $769.98 and as low as $356.14.
The top ETF exchange traded funds that IDXX belongs to (by Net Assets): VTI, VOO, QQQ, VO, IVV.
IDXX has underperformed the market in the last year with a return of -12.2%, while the SPY ETF gained +16.9%. In the last 3 month period, IDXX fell short of the market, returning -1.7%, while SPY returned +3.7%. However, in the most recent 2 weeks IDXX has outperformed the stock market by returning +5.9%, while SPY returned -0.7%.
IDXX support price is $546.67 and resistance is $564.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IDXX shares will trade within this expected range on the day.
